Results 71 to 80 of about 225,025 (354)

Intrinsically Disordered Protein‐Inspired Nanovector‐Based Coacervates for the Direct Cytosolic Transport of Biomacromolecules

Advanced Materials, EarlyView.
Intrinsically disordered protein‐inspired nanovectors (IDP‐NVs) form stable nanocoacervates (NCs) with diverse biomacromolecules. In situ conformational changes confer stability and adaptability to NCs under dynamically changing physiological conditions.
Soyeong Jin, Hyemin Park, Seuk‐Min Ryu, Dagyeong Guk, Jaeeun Lee, Seongeon Jin, Changjoon Keum, Jinyoung Park, Myoung‐Hwan Park, Chaekyu Kim, Hojun Kim, Jaegeun Noh, Kwan Hyi Lee, Ja‐Hyoung Ryu, Youngdo Jeong   +14 more
wiley   +1 more source

Advances in Adjuvanted Influenza Vaccines

Vaccines, 2023
The numerous influenza infections that occur every year present a major public health problem. Influenza vaccines are important for the prevention of the disease; however, their effectiveness against infection can be suboptimal.
Shintaro Shichinohe, Tokiko Watanabe
doaj   +1 more source

Influenza vaccine efficacy [PDF]

Canadian Medical Association Journal, 2015
I am writing in response to a recent news article[1][1] published in CMAJ . The lack of efficacy of this year’s vaccine preparation is often used as an argument against vaccination. Although the match between the vaccine H3N2 strain and the circulating H3N2 wild-type may not be optimum, we ...
openaire   +2 more sources

High‐Throughput In Vivo Screening Using Barcoded mRNA Identifies Lipid Nanoparticles With Extrahepatic Tropism for In Situ Immunoengineering

Advanced Materials, EarlyView.
A high‐throughput in vivo mRNA LNP screening platform is developed and employed to screen a large library of 122 mRNA LNPs in vivo for delivery to immune, stromal, and parenchymal cells, identifying promising LNP candidates. A novel small particle flow cytometry‐based protein adsorption analysis method is utilized to interrogate protein corona ...
Alex G. Hamilton, Ajay S. Thatte, Junchao Xu, Zhangyi Luo, Hannah C. Safford, Kelsey L. Swingle, Jenna Muscat‐Rivera, Michael Kegel, Xuexiang Han, Ryann A. Joseph, Amanda M. Murray, Hannah C. Geisler, Ricardo C. Whitaker, Lulu Xue, Roman Spektor, Jilian R. Melamed, Drew Weissman, Michael J. Mitchell   +17 more
wiley   +1 more source

Identification of novel neutralizing determinants for protection against HCV

Hepatology, EarlyView., 2022
Identification of novel neutralizing determinants for protection against hepatitis C virus. Abstract Background and Aims HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
Garazi P. Alzua, Anne F. Pihl, Anna Offersgaard, Rodrigo Velázquez‐Moctezuma, Carlos R. Duarte Hernandez, Elias H. Augestad, Ulrik Fahnøe, Christian K. Mathiesen, Henrik Krarup, Mansun Law, Jannick Prentoe, Jens Bukh, Judith M. Gottwein   +12 more
wiley   +1 more source

H1N1 Challenges Ahead [PDF]

, 2009
Examines capacities and challenges in preparing for and responding to an H1N1 flu pandemic, including vaccine issues, confusion with seasonal flu, strain on medical systems, and erosion of public health infrastructure.

core  

Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing Gn protects mice against rift valley fever virus [PDF]

, 2010
Background: Rift Valley fever (RVF) is an arthropod-borne viral zoonosis. Rift Valley fever virus (RVFV) is an important biological threat with the potential to spread to new susceptible areas. In addition, it is a potential biowarfare agent. Methodology/
A Jouan, A Zaki, B Botros, BH Bird, BS Peters, CS Schmaljohn, CS Schmaljohn, Daniel G. Bausch, DB Wallace, DV Lim, FR Toapanta, FR Toapanta, G Lorenzo, GF Meadors 3rd, H Caplen, I Watanabe, J Lubroth, J Meegan, J Naslund, J Naslund, JA Mitchell, JF Bower, JF Bower, JR Haynes, JT van Oirschot, K Keegan, K Spik, KA Hubbard, M Mkrtichyan, MA Kutzler, Mark T. Heise, MT Heise, N Lagerqvist, Nitin Bhardwaj, P Hunter, P Jansen van Vuren, P Nguku, P Pittman, P Pushko, P Vialat, PR Pittman, PW Dempsey, R Gorchakov, R Gorchakov, R Randall, RJ Daubney, S Won, SA Kamal, SR Gerrard, SR Gerrard, T Shoemaker, TA Madani, TD Green, Ted M. Ross, TM Pertmer, TM Pertmer, TM Ross, TM Ross, UB Balasuriya   +58 more
core   +4 more sources

Influenza vaccine [PDF]

Paediatrics & Child Health, 2003
V A, Pai, B V, Pai
openaire   +5 more sources

Bacterially produced recombinant influenza vaccines based on virus-like particles. [PDF]

PLoS ONE, 2013
Although current influenza vaccines are effective in general, there is an urgent need for the development of new technologies to improve vaccine production timelines, capacities and immunogenicity.
Andrea Jegerlehner, Franziska Zabel, Alice Langer, Klaus Dietmeier, Gary T Jennings, Philippe Saudan, Martin F Bachmann   +6 more
doaj   +1 more source

Computational Design and Glycoengineering of Interferon‐Lambda for Nasal Prophylaxis Against Respiratory Viruses

Advanced Science, EarlyView.
This study presents an engineered human interferon‐lambda (hIFN‐λ) as an intranasal prophylactic against respiratory viruses. By combining AI‐guided backbone redesign and glycoengineering, the authors developed a thermostable, protease‐resistant, and scalable variant with improved mucosal penetration.
Jeongwon Yun, Seungju Yang, Jae Hyuk Kwon, Luiz Felipe Vecchietti, Ji Hyun Choi, Mi‐ra Choi, Keun Bon Ku, Hyun‐Joo Ro, Kyun‐Do Kim, Meeyoung Cha, Hyun Jung Chung, Ji Eun Oh, Ho Min Kim   +12 more
wiley   +1 more source